Methods for female contraception: A model for innovation in drug delivery systems

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 5, 2009, Pages 553-557

  Merkatz, R B ^a,b   Tokay, B ^a   Sitruk Ware, R L ^a  

^a POPULATION COUNCIL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGESTONE ACETOFENIDE; ALGESTONE ACETOFENIDE PLUS ESTRADIOL ENANTHATE; CELLULOSE SULFATE; COPPER INTRAUTERINE DEVICE; DROSPIRENONE; ELCOMETRINE; ELCOMETRINE PLUS ESTRADIOL; ELCOMETRINE PLUS ESTROGEN; ELCOMETRINE PLUS ETHINYLESTRADIOL; ESTRADIOL; ESTRADIOL CYPIONATE PLUS MEDROXYPROGESTERONE ACETATE; ESTRADIOL ENANTHATE; ESTRADIOL VALERATE; ESTRADIOL VALERATE PLUS NORETHISTERONE ENANTHATE; ESTROGEN; ESTROGEN PLUS PROGESTIN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETHINYLESTRADIOL PLUS PROGESTIN; ETONOGESTREL; GESTAGEN; LEVONORGESTREL; MDTS; MEDROXYPROGESTERONE ACETATE; MULTILOAD COPPER INTRAUTERINE DEVICE; NORETHISTERONE ENANTATE; ORAL CONTRACEPTIVE AGENT; PROGERING; PROGESTERONE; PROGESTERONE RECEPTOR MODULATOR; ULIPRISNIL ACETATE; ULIPRISTAL; UNCLASSIFIED DRUG; CONTRACEPTIVE AGENT;

ACNE; AMENORRHEA; ARTICLE; BLOATING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONCEPTION; CONDOM; CONTRACEPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; FAMILY PLANNING; FAMILY SIZE; HEART INFARCTION; HORMONAL CONTRACEPTION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; LOW DRUG DOSE; MENSTRUAL IRREGULARITY; PREGNANCY RATE; PRIORITY JOURNAL; REPRODUCTIVE HEALTH; STROKE; TRANSDERMAL PATCH; UNWANTED PREGNANCY; VAGINA RING; VENOUS THROMBOEMBOLISM; DELAYED RELEASE FORMULATION; DRUG DESIGN; DRUG IMPLANT; FEMALE; INTRADERMAL DRUG ADMINISTRATION; INTRAVAGINAL DRUG ADMINISTRATION; METHODOLOGY;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, INTRAVAGINAL; CLINICAL TRIALS AS TOPIC; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVES, ORAL; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG IMPLANTS; FEMALE; HUMANS; INTRAUTERINE DEVICES;

EID: 65449174931     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.29     Document Type: Article

References (30)

1. Population Reference Bureau. Family Planning Worldwide: 2008 Data Sheet. POPLINE document no. 325417 (Population Reference Bureau, Washington, DC, 2008).
2. Sitruk-Ware, R. Delivery options for contraceptives. Drug Discov. Today 10, 977-985 (2005).
3. Frost, J.J. & Darroch, J.E. Factors associated with contraceptive choice and inconsistent method use, United States, 2004. Perspect. Sex. Reprod. Health 40, 94-104 (2008).
4. Trussell, J. & Wynn, L.L. Reducing unintended pregnancy in the United States. Contraception 77, 1-5 (2008).
5. Benagiano, G. & Primiero, F.M. Seventy-fve microgram desogestrel minipill, a new perspective in estrogen-free contraception. Ann. NY Acad. Sci. 997, 163-173 (2003).
6. Farley, T.M., Meirik, O., Chang, C.L. & Poulter, N.R. Combined oral contraceptives, smoking, and cardiovascular risk. J. Epidemiol. Community Health 52, 775-785 (1998).
7. Lidegaard, O., Edstrom, B. & Kreiner, S. Oral contraceptives and venous thromboembolism: a fve-year national case-control study. Contraception 65, 187-196 (2002).
8. Gallo, M.F., Nanda, K., Grimes, D.A., Lopez, L.M. & Schulz, K.F. 20 microg versus >20 microg estrogen combined oral contraceptives for contraception. Cochrane Database Syst. Rev. CD003989 (2008).
9. Sitruk-Ware, R. New progestagens for contraceptive use. Hum. Reprod. Update 12, 169-178 (2006).
10. Kemmeren, J.M. et al. Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke 33, 1202-1208 (2002).
11. Dinger, J.C., Heinemann, L.A. & Kuhl-Habich, D. The safety of a drospirenone-containing oral contraceptive: fnal results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 75, 344-354 (2007).
12. Sitruk-Ware, R. et al. Efects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study. J. Clin. Endocrinol. Metab. 92, 2074-2079 (2007).
13. Sitruk-Ware, R.L. et al. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen. Contraception 75, 430-437 (2007).
14. Magnusdottir, E.M. et al. The contraceptive vaginal ring (NuvaRing) and hemostasis: a comparative study. Contraception 69, 461-467 (2004).
15. Roumen, F.J. The contraceptive vaginal ring compared with the combined oral contraceptive pill: a comprehensive review of randomized controlled trials. Contraception 75, 420-429 (2007).
16. Massai, R. et al. Preregistration study on the safety and contraceptive efcacy of a progesterone-releasing vaginal ring in Chilean nursing women. Contraception 60, 9-14 (1999).
17. Audet, M.C. et al. Evaluation of contraceptive efcacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA 285, 2347-2354 (2001).
18. Lete, I. et al. Factors afecting women's selection of a combined hormonal contraceptive method: the TEAM-06 Spanish cross-sectional study. Contraception 76, 77-83 (2007).
19. Lete, I. et al. Self-described impact of noncompliance among users of a combined hormonal contraceptive method. Contraception 77, 276-282 (2008).
20. Sivin, I. et al. Contraceptive vaginal rings releasing Nestorone and ethinylestradiol: a 1-year dose-fnding trial. Contraception 71, 122-129 (2005).
21. Fraser, I.S. et al. An initial pharmacokinetic study with a Metered Dose Transdermal System for delivery of the progestogen Nestorone as a possible future contraceptive. Contraception 76, 432-438 (2007).
22. Mauck, C.K., Freziers, R.G., Walsh, T.L., Peacock, K., Schwartz, J.L. & Callahan, M.M. Noncomparative contraceptive efcacy of cellulose sulfate gel. Obstet. Gynecol. 111, 739-746 (2008).
23. Van Damme, L. et al. Lack of efectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N. Engl. J. Med. 359, 463-472 (2008).
24. Kulier, R., O'Brien, P.A., Helmerhorst, F.M., Usher-Patel, M. & d'Arcangues, C. Copper containing, framed intra-uterine devices for contraception. Cochrane Database Syst. Rev. CD005347 (2007).
25. Thonneau, P.F. & Almont, T. Contraceptive efcacy of intrauterine devices. Am. J. Obstet. Gynecol. 198, 248-253 (2008).
26. French, R. et al. Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as efective methods of preventing pregnancy. Cochrane Database Syst. Rev. CD001776 (2004).
27. Sivin, I. et al. The performance of levonorgestrel rod and Norplant contraceptive implants: a 5 year randomized study. Hum. Reprod. 13, 3371-3378 (1998).
28. Power, J., French, R. & Cowan, F. Subdermal implantable contraceptives versus other forms of reversible contraceptives or other implants as efective methods of preventing pregnancy. Cochrane Database Syst. Rev. CD001326 (2007).
29. TM medroxyprogesterone acetate injectable suspension 104 mg/0.65 mL. New York: Pharmacia and Upjohn, Division of Pfzer, 2005.
30. Gallo, M.F., Grimes, D.A., Lopez, L.M., Schulz, K.F. & d'Arcangues, C. Combination injectable contraceptives for contraception. Cochrane Database Syst. Rev. CD004568 (2008).